Dyax

Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory indications. We utilize our proprietary drug discovery technology, phage display, to identify antibody, small protein and peptide compounds for clinical development. Dyax also leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Click here to learn more.